Current status of differetiated radioactive iodine-resistant thyroid cancer case report of successful long-term treatment with sorafenib

Thyroid cancer is one of the most widespreaded malignant endocrine tumors. Morbidity is constantly increasing in the world and in Russian Federation during last decade [1, 2]. So, in the United States marked annual increase of diagnosed cases of thyroid cancer by 6.4% with increasing of mortality by 0.9% [3]. In Russian Federation marked annual increase of diagnosed cases by 5.4% in 2003-2013. In 2013 in Russian Federation diagnosed 9624 new cases of thyroid cancer with morbidity 93.2 on 100 000 citizens [1]. Differentiated thyroid cancer is more than 90% of all cases of thyroid cancer [4].